Five companies, read properly

Built from five fiscal years of primary filings (FY2021-FY2025, year ended 30 April, plus the 12 May 2026 FY2026 trading update), read in chronological order without reference to the share price at any point. Prepared 29 August 2026. Companion workbook: KMK_multi_year_model.xlsx.

Executive summary

Kromek Group plc is a small, Durham-based UK technology company that designs and manufactures Cadmium Zinc Telluride (CZT) radiation-detector materials and modules, sold either as components to larger OEM systems integrators or built into its own end products, across three principal markets: medical imaging (chiefly SPECT/CT nuclear-medicine cameras), CBRN (chemical, biological, radiological, nuclear) threat detection, and biological-threat detection. For most of the five years reviewed here it was a persistently loss-making, cash-consuming small-cap, funding continued R&D capitalisation through a mix of equity raises, a convertible loan note, and — across FY2024-FY2025 — a secured loan from a significant shareholder. FY2025 changed that picture materially, and did so for a specific, identifiable reason rather than a broad-based turnaround.

Revenue grew from £10.4m in FY2021 to £26.5m in FY2025 (a 2.6x increase), but the FY2025 step-change specifically — revenue +37% year-on-year, gross margin nearly doubling to 80.9%, adjusted EBITDA of £10.3m and the company's first full-year statutory profit before tax (£3.1m) in the period reviewed — is substantially attributable to a single transaction: £16.5m of licensing revenue and a $25.0m cash receipt under Enablement and Patent Licensing Agreements signed with Siemens Healthineers in January 2025, part of a four-year, non-exclusive, SPECT-only agreement worth up to $37.5m. That cash was used to repay in full a related-party secured loan the company had drawn from Polymer N2 Ltd, an affiliate of Polymer Holdings, one of Kromek's largest shareholders.

Two things stand out favourably across the five years read: no annual report carried a qualified audit opinion or a formal going-concern material uncertainty, despite several years running close to facility-renewal deadlines; and the Siemens transaction is a genuine, verifiable commercial and technical validation of Kromek's detector technology by a major medical-imaging OEM, not merely an accounting or financing manoeuvre. Two things stand out as caveats for anyone valuing the business from these filings: FY2025's headline profitability is concentrated in one large, largely non-recurring item, and the relationship between Kromek and its largest shareholder — who has also, through an affiliate, been its secured lender — is a governance fact that sits independently of anything on the income statement.

Valuing the company on revenue and earnings multiples appropriate to a small radiation-detection technology business — deliberately built without looking at the current share price — produces a primary (EV/Revenue-based) range of approximately 2.3p (low) to 3.9p (central) to 6.4p (high) per share, and a cross-check (EV/EBITDA-based) range of approximately 9.9p to 21.1p. These two methods diverge sharply, for a specific and identifiable reason discussed in full below and in the companion workbook's Valuation tab — that divergence is reported as a finding, not smoothed into a single blended number.

Company background

Kromek listed on AIM in 2013 and describes itself as a supplier of detection technology solutions built around its own proprietary CZT (Cadmium Zinc Telluride) semiconductor material — a room-temperature radiation detector material that, unlike some competing technologies, does not require cryogenic cooling, which is one of the company's stated technical differentiators. The Group organises its activity around three principal end markets: medical imaging (supplying detector modules to OEM manufacturers of SPECT and SPECT/CT nuclear-medicine cameras, and pursuing photon-counting CT detector development), CBRN detection (radiation and nuclear-threat detection systems for security, defence and critical-infrastructure customers), and biological-threat detection (automated, wide-area detection of airborne biological agents).

For statutory reporting purposes the company's segmentation basis has itself changed over the period: FY2021-FY2024 annual reports split revenue geographically between UK Operations and US Operations (reflecting that the US unit has historically focused more on advanced imaging and the UK unit more on CBRN and biological-threat detection, though the company is explicit that this split is not rigid). From the FY2025 Annual Report, Kromek began reporting on a two-division basis instead -- Advanced Imaging and CBRN/Bio-detection -- first previewed at a Capital Markets Day investor presentation in June 2025. This is a genuine improvement in how the business explains itself to investors, but it also means a clean five-year like-for-like segment history does not exist in the primary filings; the Company KPIs tab in the companion workbook uses the restated FY2024 comparator plus approximate, investor-presentation-sourced figures for FY2022-FY2023 and flags FY2021 as unavailable on this basis.

A structural feature of the business worth understanding from the outset: Kromek has historically capitalised a large share of its R&D spend on the balance sheet as an intangible asset (in accordance with IAS 38) rather than expensing all of it through the income statement, and has run at or near break-even-to-loss on an adjusted EBITDA basis for most of the period. R&D capitalisation fell steadily from 52.8% of revenue in FY2021 to 16.5% in FY2025 as revenue grew far faster than R&D spend -- a genuine sign of operating leverage, discussed further below.

Development, year by year

FY2021 — pandemic disruption, continued losses

Revenue fell to £10.4m (FY2020: £13.1m) as COVID-19 disrupted customer order patterns and shipments in the first four months of the year, with a resumption of activity in the second half. Gross margin held at 48.4%. Adjusted EBITDA loss widened to £1.7m (FY2020: £0.4m loss) and the statutory loss before tax was £6.3m -- though this compares favourably on paper to FY2020's £18.3m loss largely because FY2020 carried a large exceptional impairment charge, a base-effect comparison rather than genuine year-on-year operating improvement. A £12.2m net equity raise funded continued R&D capitalisation (£5.5m) through a year in which operating cash flow remained negative.

Revenue mix shifted notably toward R&D contract revenue (44% of the total, up from 21% in FY2020), which management attributed primarily to biological-threat detection development activity -- a reminder that "revenue growth" and "product sales growth" are not always the same thing for this company.

FY2022 — steady execution against a difficult supply-chain backdrop

Revenue grew 16% to £12.1m, but gross margin was squeezed to 46.8% (from 48.4%) by global supply-chain inflation, and the adjusted EBITDA loss narrowed only modestly to £1.16m. Cash fell sharply, from £15.6m to £5.1m, as the prior year's equity raise was consumed by continued R&D capitalisation (£5.6m) and working capital -- moving the balance sheet from a net cash position of £7.4m to a net debt position of £1.4m within a single year, the first such swing in the period reviewed.

This was also the one year in the five-year window where the directors' own going-concern disclosure used language that could "cast significant doubt" on the Group's ability to continue as a going concern, tied to a forecast breach of a bank net debt:EBITDA covenant and a conditional waiver from the lender. The auditor's own opinion did not, in the event, treat this as a formal material uncertainty, and no liquidity crisis in fact developed -- but the gap between the directors' risk language and the auditor's conclusion is worth noting as a point of internal tension in that year's reporting.

FY2023 — a genuine, broad-based operating improvement

Revenue grew 44% to a then-record £17.3m, described by the company as record performance in both its advanced imaging and CBRN detection business lines. Gross margin recovered to 51.6% and the adjusted EBITDA loss narrowed further to £1.0m, with the second half of the year alone adjusted-EBITDA-positive (£1.7m), more than offsetting a weaker first half (£2.7m loss). A £2.8m convertible loan note issue supplemented financing during the year, and a post-year-end £7.4m placing, subscription and open offer -- backed by a financial-support letter from a large shareholder -- underpinned the going-concern basis; the balance sheet nonetheless ended the year in a £7.8m net debt position.

Unlike FY2022, this year's improvement was broad-based rather than a single-item effect: both principal business lines grew, gross margin expanded, and the business achieved second-half adjusted-EBITDA profitability for the first time in the period reviewed.

FY2024 — the adjusted-EBITDA milestone, and a related-party refinancing

Revenue rose 12% to £19.4m and gross margin improved further to 55.2%. Adjusted EBITDA turned positive for the first time in the five years reviewed, at £3.1m, which the company states came in ahead of market expectations -- a genuine, disclosed milestone. A statutory loss before tax of £3.5m was nonetheless still reported. On the divisional basis later restated in the FY2025 Annual Report, this year's adjusted-EBITDA milestone was carried by the CBRN/Bio-detection division (£4.2m adjusted EBITDA) while Advanced Imaging ran an operating loss of £4.3m -- the opposite pattern to FY2025, discussed below.

During the year, the Group's £5.0m HSBC revolving credit facility was refinanced with a new £5.5m secured term loan from Polymer N2 Ltd, described by the company as an affiliate of "an existing and significant shareholder in the Company." The loan carried a fixed 9.5% interest rate, payable quarterly, with Kromek holding the option to settle interest through the issue of new ordinary shares rather than cash. Refinancing a facility with a related-party lender, on terms that include a potentially dilutive share-settlement option, is a governance point independent of the P&L -- discussed fully in the companion workbook's Ownership tab.

FY2025 — the transformational year, driven by a single transaction

Revenue jumped 37% to £26.5m, gross margin nearly doubled to 80.9%, adjusted EBITDA reached £10.3m, and the Group reported its first full-year statutory profit before tax (£3.1m) in the five years reviewed. This step-change is substantially attributable to £16.5m of licensing revenue and a $25.0m cash receipt recognised under the Enablement and Patent Licensing Agreements signed with Siemens Healthineers in January 2025 (part of a four-year, non-exclusive, SPECT-only agreement worth up to $37.5m in total, of which a further $2.5m milestone payment was received in August 2026 and $5.0m remains outstanding, expected by April 2029). That cash was used to repay the Polymer N2 Ltd related-party loan in full.

On the restated divisional basis, Advanced Imaging swung from a £4.3m operating loss in FY2024 to a £7.8m operating profit in FY2025 -- substantially licensing-revenue-driven -- while CBRN/Bio-detection moved the other way, from a £2.9m operating profit to a £3.0m operating loss. Excluding the Siemens item, the company's own commentary at the 12 May 2026 trading update describes "good underlying growth" in CBRN Detection and Advanced Imaging growth of "over 200% year-on-year," which is a genuinely positive underlying signal -- but the reported headline profit for FY2025 as a whole is not representative of a repeatable run-rate, which is the central reason the companion workbook's Valuation tab treats FY2025 earnings with caution.

FY2026 (trading update only, 12 May 2026 — most recent data point, full-year results due September 2026)

The company stated it expects to report FY2026 revenue and profit before tax "in line with market expectations," explicitly citing consensus estimates of £27.2m revenue and £2.15m PBT. CBRN Detection delivered revenue growth despite delays in some governmental contracts reaching the procurement stage; Advanced Imaging faced supply-chain and order-timing disruption in the first half, offset by a large new customer order in the second half. Kromek's sole broker, Cavendish Capital Markets (also its Nominated Adviser), reiterated a Buy rating the same day with a 26p price target and its own estimates of £27.1m revenue and £2.3m adjusted PBT. FY2026 full-year results had not been published as of this document's preparation.

Year-by-year summary

Full line-item detail, formulas, and citations are in the companion workbook. Figures in £m are rounded from the £'000 figures in the Income Statement tab; PBT figures in parentheses denote losses.

Industry and structural quirks worth understanding

• R&D capitalisation, not just R&D spend, is the number that matters for cash flow. Kromek capitalises a large share of its development spend as an intangible asset under IAS 38 rather than expensing it -- this flatters reported operating profit relative to a company that expenses all R&D, but the cash actually leaves the business either way. The workbook's Company KPIs tab tracks R&D capitalised as a % of revenue specifically because it fell from 52.8% to 16.5% over five years, a genuine and meaningful operating-leverage signal that a glance at the income statement alone would not reveal.
• Licensing and milestone revenue from OEM partners can be lumpy and transformational in a way that ordinary product revenue is not. The Siemens Healthineers agreement is the clearest example in this five-year window, but the structure (upfront/milestone cash payments plus a smaller ongoing royalty stream) is common in this industry for companies that license detector IP into larger systems businesses rather than selling finished systems directly -- it means a single new OEM agreement can move the P&L more than a full year of incremental product sales.
• CBRN and nuclear-security end markets are heavily influenced by government procurement cycles, which the company itself describes as subject to timing delays ("delays in certain governmental contracts progressing to the procurement stage," per the FY2026 trading update) -- a demand-timing risk that is largely outside the company's control and can shift revenue between financial years without changing the underlying commercial pipeline.
• Small-cap AIM technology companies in this space are frequently financed through a mix of instruments not seen in larger, self-funding businesses -- equity placings, convertible loan notes, and related-party or shareholder-provided secured debt (as with Polymer N2 Ltd here) are all part of Kromek's five-year financing history, and each carries different dilution and governance implications worth distinguishing rather than treating as interchangeable "financing."
• A statutory segment-reporting basis can change even for a company with a consistent underlying business -- Kromek moved from geographic (UK/US) to divisional (Advanced Imaging/CBRN-Bio) segment reporting between FY2024 and FY2025, which is a genuine improvement in investor communication but also means a clean five-year like-for-like segment series does not exist without combining sources of varying precision, as the companion workbook's Company KPIs tab does explicitly and transparently.

Recurring themes across the period

A shareholder that has also been the company's secured lender. Polymer Holdings has been a Kromek shareholder since at least FY2021 (5.08% then; 15.29% as at 31 August 2025, the most recent date disclosed), and its affiliate Polymer N2 Ltd was Kromek's secured term-loan lender across FY2024-FY2025 (£5.5m plus a further £3.4m tranche, at a fixed 9.5% rate with a share-settlement option on interest), fully repaid in FY2025 from Siemens Healthineers proceeds. This is not, on its own, evidence of any wrongdoing -- a large, supportive shareholder providing financing when a company needs it can be a genuinely aligned, stabilising relationship, and the company disclosed the arrangement clearly as a related-party transaction throughout. But a shareholder that is simultaneously a secured creditor, with an interest-settlement option that can be dilutive at the lender's discretion, has a structurally different relationship with the company than a passive institutional holder of the same size, and is worth tracking specifically -- see the companion workbook's Ownership tab for the full picture, including the dispersed remainder of the share register.

Beyond the ownership point, three further patterns recur consistently enough across five years of filings to be worth naming.

• Persistent reliance on external financing to fund R&D capitalisation. Every year but FY2025 involved either an equity raise (FY2021, FY2024), a convertible loan note (FY2023), or shareholder-affiliated secured debt (FY2024-FY2025) to fund continued development spend and working capital. FY2025 was the first year the business substantially funded itself from operations and a single large commercial transaction rather than a capital markets or lender transaction.
• A clean audit record despite recurring near-term liquidity pressure. No qualified audit opinions and no formal material-uncertainty/going-concern paragraphs were issued in any of the five years reviewed, notwithstanding several years running close to covenant thresholds or facility-renewal deadlines, and one year (FY2022) where the directors' own risk disclosure used "significant doubt" language that the auditor's own opinion did not, in the end, adopt.
• Concentration of FY2025's improvement in one division and one transaction. Advanced Imaging swung from a £4.3m operating loss (FY2024) to a £7.8m operating profit (FY2025) substantially on the back of the Siemens licensing item, while CBRN/Bio-detection moved from profit to loss over the same period -- a valuation built on FY2025 run-rate earnings without adjustment would materially overstate normalised, repeatable profitability, which is the central reason the companion workbook's Valuation tab uses revenue rather than earnings as its primary multiple base.

Value range

Kromek is valued here using EV/Revenue as the primary multiple, cross-checked against EV/EBITDA -- the standard framework for a small, sub-scale technology/hardware company without a multi-year track record of stable earnings to normalise, and for which a bank-style asset-based or P/E approach is not appropriate. Both methods were checked against 5 sourced peer/transaction multiples (Detection Technology Oyj, Mirion Technologies, OSI Systems, Teledyne Technologies, and the Smiths Detection sale to CVC Capital Partners) and, separately, against Kromek's own sell-side broker coverage and guidance. This was built entirely from the primary filings above and deliberately without reference to KMK's current share price at any stage.

The central EV/Revenue multiple of 0.9x is set to match Detection Technology Oyj, the closest technology and scale comparable of the five (the peer group ranges 0.89x-4.79x, median ~2.27x) -- a deliberately conservative anchor given Kromek's much smaller scale, thin free float, single-broker coverage, and the one-off composition of a meaningful share of FY2025 revenue. Applied to FY2025 revenue of £26.5m, plus FY2025 net cash of £1.2m, divided across 641.5m shares in issue, this produces the primary value range below.

Full sensitivity model with editable assumptions, and the full 5-peer comparison with sourced multiples, is in the companion workbook's Valuation tab. Move any yellow input cell there and every downstream figure recalculates.

Why the two methods diverge, and how to read that

The EV/Revenue and EV/EBITDA ranges do not overlap (2.3-6.4p versus 9.9-21.1p) and are deliberately not blended into one number here -- that divergence is reported as a finding, not resolved by picking a number in between. The reason is specific: FY2025 adjusted EBITDA (£10.3m, up from a £1.2m loss the year before excluding rounding) is heavily inflated by the one-off Siemens licensing recognition, so applying even a conservative peer-level EBITDA multiple to that base assumes a level of repeatable profitability the business has not yet demonstrated over a full cycle. Revenue, while it also includes the one-off licensing amount, is a somewhat less distorted base because the underlying £10.0m of FY2025 product and R&D-contract revenue sits alongside it without being run through a profit multiple. This is why EV/Revenue is used as the primary method and EV/EBITDA only as a cross-check and upper reference point.

Applying the same central 0.9x multiple to the company's own FY2026 consensus revenue figure (£27.2m) rather than FY2025 actual revenue (£26.5m) moves the central estimate only marginally, to approximately 4.0p -- the range is not especially sensitive to which of these two similar revenue bases is used. Kromek's own broker, Cavendish, carries a 26p price target, roughly 4-11x this workbook's primary range; that gap is stated plainly rather than closed, and most likely reflects an earnings-multiple or discounted-cash-flow approach that capitalises continuing Siemens royalty/option value and a re-rating case for the CBRN pipeline that this deliberately conservative, revenue-multiple-only approach does not attempt to capture.

Limitations and what would sharpen this further

• None of the figures in this document or the companion workbook have been checked against a second, independent source beyond the primary filings read in this session. Per the project's standing rule, no number here should enter an investment decision until independently verified.
• Kromek's divisional (Advanced Imaging / CBRN-Bio) revenue split is only available on a statutory, restated basis for FY2024-FY2025; the FY2022-FY2023 figures used in the companion workbook are approximate, investor-presentation-sourced numbers, and FY2021 is not available on this basis at all.
• The FY2025 Annual Report itself contains two different, non-reconciling FY2024 comparative figures for Advanced Imaging revenue in different sections of the same document (£9.0m in the Highlights and the statutory segment note versus £9.4m in the CFO's Review narrative) -- a drafting inconsistency in the source document, not an extraction error here, and a reminder to rely on the primary tables over any single narrative sentence.
• Board changes announced in the FY2025 Annual Report (the departure of two long-serving Non-Executive Directors and the appointment of a new one at the AGM) were not confirmed as completed in any later document reviewed for this exercise -- treat them as announced intent, not confirmed fact, until checked against a subsequent filing.
• This valuation range would sharpen materially with: audited FY2026 full-year results (due September 2026), which would show whether FY2025's underlying (ex-Siemens) growth in both divisions continued; more granular disclosure of the ongoing royalty economics of the Siemens agreement beyond the milestone payments disclosed to date; and a second, independent sell-side view to triangulate against Cavendish's coverage, given Kromek's broker coverage is effectively single-source.
• This document deliberately does not compare the value range above to KMK's current market price. That comparison is the next, separate step in the process, to be taken only after the figures above have been checked.

Kromek Group plc · LSE AIM: KMK · Research prepared 29 August 2026

Built from five fiscal years of primary filings, read in chronological order without reference to the share price at any point. Every figure in the companion workbook traces to a row in the tables below. Where a figure is derived, assumed or taken from a secondary source, it is identified as such rather than presented alongside reported figures.

Document set

Statement-level provenance

Non-primary and flagged items

Standing limitations

FY2025 profitability rests substantially on a single licensing transaction with a fixed term. The two valuation methods in the workbook diverge sharply for this reason, at 2.3p–6.4p on the primary approach against 9.9p–21.1p on EV/EBITDA. The divergence is reported rather than averaged away, because the ambiguity is a genuine feature of the company rather than an artefact of the method.

Related-party financing runs through the period. The ownership tab exists partly to make that visible alongside the balance sheet rather than in a note behind it.

Built from six fiscal years of primary filings (FY2020-FY2025, year ended 31 December, plus the 22 July 2026 H1 2026 trading update and the 27 August 2026 Searches UK disposal announcement), read in chronological order without reference to the share price at any point. Prepared 29 August 2026. Companion workbook: NAH_multi_year_model.xlsx.

Executive summary

NAHL Group plc is a UK consumer-legal-services marketing and services business, best known for its National Accident Helpline personal-injury brand, now organised into two divisions: Consumer Legal Services (CLS — personal-injury claims marketing and processing, plus a small residential-property-searches business pending disposal) and Critical Care (specialist catastrophic- and serious-injury services for claimants and defendants, delivered through Bush & Co.). The single dominant fact shaping every one of the six years reviewed here is the UK's 2021 "whiplash reform" (the Civil Liability Act 2018, implemented 31 May 2021), which raised the small-claims track limit for road-traffic-accident personal-injury claims to £5,000 and introduced the Official Injury Claim portal for litigants in person — a structural shrinkage of the market NAHL's core Personal Injury business depends on, which every annual report FY2020-2025 references directly.

NAHL saw this coming and responded years in advance: it converted its Personal Injury referral arrangement into National Accident Law, an SRA-regulated, wholly-owned law firm, so that its revenue is earned as consumer-legal-services economics rather than a personal-injury referral fee (which has been illegal in England & Wales since LASPO 2012/13). That structural pivot was substantially complete before the reform took effect in 2021, and it is the reason NAHL remained profitable through the reform's implementation even as revenue and claim volumes fell. It did not, however, fully insulate the business from the market's long-run contraction: RTA claim registrations have fallen roughly 40-46% versus pre-pandemic 2019 levels on the company's own market data, and this cumulative pressure led the Board to take a £39.9m non-cash goodwill impairment on the Personal Injury cash-generating unit in FY2024.

The six-year financial picture is one of resilience through a hard structural shock rather than either a growth story or a distress story. Revenue held in a narrow £38.8m-£42.2m band across all six years; profit before tax was small but positive in four of the six years (FY2020: -£0.2m, FY2021: £0.2m, FY2022: £0.6m, FY2023: £0.6m), collapsed to -£39.1m in FY2024 on the impairment alone (underlying operating profit that year was still £3.9m), and then recovered strongly to £4.4m PBT in FY2025 as underlying operating profit rose 86% to £7.3m. Net debt has fallen every single year of the period, from £16.3m at FY2020 year end to £3.2m at FY2025 year end and £1.0m by 30 June 2026 — a consistent, disciplined debt-paydown priority maintained even through the weakest trading years.

Two governance facts sit alongside the operating story and are treated fully in the companion workbook's Ownership tab: an Alternative Business Structure (ABS) mechanism (via Project Jupiter Limited's board-appointment rights over two consolidated law-firm LLPs) that is the precise legal architecture keeping the CLS revenue model lawful, and a ≥10% shareholder (Sacisa Limited, 11.90% at FY2025 year end) that on further research turns out to be a long-standing, unchanged holding controlled throughout by one individual, Bhavesh Patel, rather than a new or unexplained entrant. Valuing the business on EV/EBITDA (primary) and EV/Revenue (cross-check) multiples appropriate to an asset-light UK legal-services marketing business — built without reference to the current share price — produces a primary range of approximately 40p (low) to 59p (central) to 86p (high) per share, with a broadly overlapping cross-check range of approximately 18p to 60p. A segment-differentiated sum-of-the-parts cross-check, valuing Consumer Legal Services and Critical Care separately, is also included and lands with its central case close to, but below, the group-level method's high case.

Company background

NAHL Group plc listed on AIM in 2014 and describes itself as a leader in the UK consumer legal services market. It operates through two divisions. Consumer Legal Services provides outsourced marketing services to panel law firms through its National Accident Helpline brand, and claims-processing services directly to individuals through its own integrated law firms — National Accident Law (100%-owned), Your Law LLP (75% capital contribution) and Law Together LLP (50% capital contribution, in partnership with HCC Solicitors) — plus, until its announced 2026 disposal, residential-property searches through Searches UK Limited. Critical Care, delivered through Bush & Co., provides expert-witness reports, care-package assessment and case-management services in the catastrophic- and serious-injury market, serving both claimants and defendants — a structurally different, non-claims-volume-dependent business from CLS.

The regulatory backdrop is central to understanding this company: referral fees for personal-injury claims have been banned in England & Wales since LASPO 2012/13, which is why a marketing business in this space cannot simply sell leads to law firms for cash. NAHL's answer, built out over several years and substantially complete before the 2021 whiplash reform took effect, was to become the law firm itself for a majority of its Personal Injury enquiries — National Accident Law captures legal-services fee income directly, while enquiries directed to third-party panel firms are charged a "cost-plus marketing services" fee rather than a referral fee. The Your Law and Law Together LLPs are consolidated as full subsidiaries under IFRS 10, not because NAHL holds a capital majority in either (75% and 50% respectively) but because its wholly-owned Project Jupiter Limited is entitled to appoint 60% of each LLP's Management Board; the minority partner's economic share is carried as a liability ("member capital and current accounts"), not as non-controlling equity interest — a genuine accounting-and-legal-structure nuance worth understanding before comparing NAHL's balance sheet mechanically to a simpler corporate group.

The single largest external driver across the whole six-year window is the 2021 whiplash reform itself: it raised the small-claims track limit for road-traffic-accident personal-injury claims to £5,000 (from £1,000-£1,500 depending on claim type) and introduced the Official Injury Claim (OIC) online portal for litigants in person to pursue smaller claims without a solicitor. NAHL's own market commentary, repeated with only minor wording changes across all six annual reports, is that this removed a large share of the economic value from the pre-reform RTA personal-injury market — the company's own market-data citations put registered RTA claims 40-46% below pre-pandemic 2019 levels by FY2023-2024. Reading any single year's numbers in isolation from this backdrop risks materially misinterpreting them.

Development, year by year

FY2020 — COVID disruption, and a well-timed strategic pivot completed ahead of reform

Revenue fell to £40.9m (2019: £51.3m) as COVID-19 disrupted claim-generation activity for several months, and the Group completed the disposal of its loss-making National Law Associates LLP interest for nil consideration. A statutory loss before tax of £0.2m was reported, a considerable improvement on 2019's much larger loss (which had been driven by a £7.9m impairment of Residential Property goodwill). £1.35m of exceptional costs related to strategic and reorganisation activity, office consolidation, and due diligence on an unsolicited approach for the Group that did not proceed, with no further detail disclosed.

The year's most consequential development was not financial but structural: management used the pandemic disruption productively to complete the multi-year transformation of the Personal Injury business from a claims-referral company into an SRA-regulated law firm (National Accident Law), positioned well ahead of the confirmed 31 May 2021 whiplash-reform implementation date. By year end, over 80% of new RTA claims were already being placed into NAL. This was a genuinely well-timed pivot, executed years ahead of the regulatory deadline it was designed to address — though the CEO who led it, Russell Atkinson, resigned in September 2020 without a permanent successor named before year end, opening an unusual leadership gap discussed further below.

FY2021 — the reform lands, and the pivot begins paying off

Revenue fell further to £38.9m as the whiplash reform took effect on 31 May 2021, but underlying operating profit and profit before tax both turned positive (£0.2m PBT) as National Accident Law began capturing more of the value previously shared with third-party panel firms: enquiries placed into NAL rose 130% year-on-year and NAL's share of total Group enquiries rose from 10% to 26%. No exceptional items were recognised in the year.

The roughly 11-month CEO vacancy that opened with Russell Atkinson's September 2020 resignation ended in August 2021 with James Saralis, previously the Group's CFO, appointed Chief Executive, with Chris Higham stepping up as acting CFO (formally confirmed in the role in September 2022). The strategic bet made in FY2020 began paying off in precisely the year the reform actually landed — a reasonably clean piece of execution against a plan telegraphed a full year earlier — though the extended CEO gap itself is a governance point worth noting, even though the eventual internal promotion provided continuity rather than disruption.

FY2022 — growth against a shrinking underlying market

Revenue grew to £41.4m, a multi-year high at the time, and profit before tax improved to £0.6m. The company's own market commentary struck a more cautious tone about the underlying claims market even as its own numbers improved: RTA claim registrations fell a further 7% year-on-year (down 43% versus pre-pandemic 2019), and for the only year in the six reviewed, one customer accounted for 10.0% of Group revenue. Gillian Kent, an independent Non-Executive Director, resigned from the Board in September 2022 — the only board change that year, with no reason stated in the documents reviewed.

Revenue growth in a market the company itself describes as shrinking suggests continued share gains and/or a beneficial NAL revenue-mix effect rather than any tailwind from the underlying claims environment — a reasonable execution story on its face, though the one-year customer-concentration flag and an unexplained NED departure are both details worth tracking rather than dismissing as noise.

FY2023 — record revenue, and a disciplined portfolio-pruning disposal

Revenue grew again to £42.2m, the highest of the six years reviewed, and profit before tax held at £0.6m. The Group disposed of Homeward Legal Limited, a small Residential Property lead-generation business, for a nominal £117,000 — consistent with a strategy of concentrating capital on the core Personal Injury and Critical Care businesses rather than holding a marginal, non-core asset indefinitely. Market data cited by the company showed RTA claim registrations down a further 5% year-on-year and 46% versus 2019, with an independent survey the company itself commissioned estimating that over £1.4bn of potential personal-injury settlements went unclaimed in 2022 — a signal, in the company's own framing, of a permanently smaller addressable market rather than a temporary post-reform dip.

The consistent, multi-year citation of shrinking claim-registration data in the company's own market commentary across FY2022 and FY2023 reads, in hindsight, as management being realistic about the structural size of its addressable market well before the FY2024 impairment decision discussed next — i.e. that write-down should not have come as a surprise to an attentive reader of the two prior years' reports.

FY2024 — a large, overdue impairment, and a division put up for sale

A statutory loss before tax of £39.1m was driven almost entirely by a £39.9m non-cash impairment of the Personal Injury cash-generating unit's goodwill, following a further reduction in panel-firm enquiry demand that the Board concluded was now a permanent, not temporary, feature of the post-reform market. Revenue fell 8% to £38.8m. The Board also announced a process to explore the sale of the Critical Care business (Bush & Co.), classified as held for sale/discontinued at year end, with the stated aim of realising cash for the Group and revisiting strategic options for the remaining Consumer Legal Services business. Notably, underlying operating profit fell only 4% to £3.9m and net debt continued its multi-year decline even in this, the weakest headline year in the period.

Taking a large, overdue non-cash impairment rather than continuing to carry an asset value the trading evidence no longer supported is the right call, even though it produces an ugly statutory headline — and the prior two years' own market commentary (see FY2022-FY2023 above) suggests management was not blindsided by this outcome. Launching a sale process for a profitable, well-performing division to fund optionality elsewhere is a legitimate strategic move on its face, but it also introduced a year of operational distraction and uncertainty for a business that was not, on the operating numbers alone, in obvious need of a sale.

FY2025 — a strong operating recovery, and a sale process that ended without a sale

Revenue grew 3% to £40.0m and underlying operating profit rose 86% to £7.3m (statutory PBT £4.4m; underlying PBT more than 250% higher at approximately £5.0m) — a genuinely strong recovery year on the operating numbers. The Critical Care sale process launched the prior year, however, concluded WITHOUT a sale on 19 June 2025; the company's own stated reason was that none of the proposals received would have delivered appropriate value to shareholders. The Board then began an open-ended process to explore alternative options to accelerate shareholder value, still unresolved as of the July 2026 half-year trading update. Net debt fell to a 10-year low of £3.2m. Sacisa Limited also appeared for the first time as a ≥10% substantial shareholder in this year's disclosures — though, as discussed below, this is the same individual's holding already disclosed via a March 2025 regulatory filing, essentially unchanged since, not a newly-built position.

Walking away from a sale process rather than accepting a low-value bid is a defensible, shareholder-protective decision on its face, and the underlying operating recovery this year is real and substantial. But the company discloses essentially no further detail anywhere in the documents reviewed about why the Critical Care sale attracted no acceptable offer — financing conditions, price gap, and bidder identity are all unstated — and the subsequent 13-plus months of an open-ended, still-unresolved "exploring alternative options" process is the kind of prolonged strategic ambiguity that carries a real cost in management attention and market credibility, even where the eventual outcome proves sound.

H1 2026 (interim, most recent data point — trading update 22 July 2026, not scored; plus the 27 August 2026 Searches UK disposal announcement)

Revenue rose 3% to approximately £19.7m and underlying operating profit rose approximately 8% to £3.4m, with free cash flow up 42% to £2.1m and net debt down 68% in the half to £1.0m. National Accident Helpline enquiries grew 11%, though enquiries newly placed into NAL fell slightly as management trials new, initially more expensive, marketing channels to improve the resilience of lead generation. Critical Care revenue grew 3%, with strong expert-witness growth offsetting continued softness in case-management services; management is shifting case-management delivery toward a larger in-house team. The Board guided that H2 2026 settlements and revenue from NAL are expected to be notably lower, reflecting reduced enquiries placed into NAL over the past two years, and that net debt would rise moderately in H2 while remaining well below the FY2025 year-end level.

On 27 August 2026 — the day before this document was prepared — the company announced a binding conditional agreement to sell Searches UK Limited, its residential-property-searches business, to TM Group (UK) Limited for an enterprise value of £1,234,000 (5.25x trailing twelve-month Adjusted EBITDA of £235,000), with proceeds earmarked to reduce the Group's revolving credit facility. Completion is subject to CMA approval and is not expected before 1 October 2026. This disposal is immaterial in scale to the value range calculated in this document (well under 1% of the low-case equity value) and has not been reflected in the earnings or revenue base used for valuation below, given it had not completed as of this document's preparation. The Board's broader "exploring alternative options to accelerate shareholder value" process remained unresolved as of this update.

Year-by-year summary

Full line-item detail, formulas, and citations are in the companion workbook. Figures in £m are rounded from the £'000 figures in the Income Statement tab; PBT figures in parentheses denote losses. Underlying operating profit is Gross profit less Administrative expenses before exceptional items, on a consistent basis across all six years (see the Income Statement tab's comment on the FY2020 presentational reconciliation).

Industry and structural quirks worth understanding

• A single piece of legislation dominates six years of results. The 2021 whiplash reform (Civil Liability Act 2018) is, by a wide margin, the single most important lens for reading this company's numbers — more so than any individual year's management decisions. Every annual report FY2020-2025 references it or its continuing aftermath as the primary driver of Personal Injury revenue trends.
• Referral fees for personal-injury claims are illegal in England & Wales (since LASPO 2012/13) — which shapes NAHL's entire revenue model. The company cannot simply sell claim leads to law firms for cash; instead it operates its own SRA-regulated law firm (National Accident Law) for a majority of enquiries, and charges third-party panel firms a "cost-plus marketing services" fee, not a referral fee, for the remainder. Understanding this distinction is essential to interpreting the Consumer Legal Services segment's economics correctly.
• LLP consolidation here follows board-control rights, not capital ownership percentages. Your Law LLP (75% NAHL capital contribution) and Law Together LLP (50% NAHL capital contribution, with HCC Solicitors as partner) are both consolidated as full subsidiaries under IFRS 10 because NAHL's wholly-owned Project Jupiter Limited can appoint 60% of each LLP's Management Board — not because of the capital split. The minority partner's economic share appears as a liability, not as non-controlling equity interest, which affects how the balance sheet should be read relative to a simpler corporate structure.
• Critical Care (Bush & Co.) is a structurally different, non-claims-volume-dependent business bolted onto a claims-volume-dependent core. Its expert-witness, care-package and case-management services serve both claimants and defendants in catastrophic- and serious-injury matters, and its performance has moved largely independently of — and in FY2025 offset — the Personal Injury business's post-reform pressures, which is precisely why it became a disposal candidate in FY2024-2025 despite performing well operationally.
• The company's own market-data citations (RTA claim registrations, the independent unclaimed-settlements survey) are a rare example of a UK small-cap consistently disclosing detailed, sourced market-contraction data across multiple consecutive annual reports — useful for triangulating whether a given year's results reflect company-specific execution or market-wide movement, and unusually transparent for a company of this size.

Recurring themes across the period

Sacisa Limited / Bhavesh Patel, 11.90% — investigated and resolved (updated 29 Aug 2026). This holding first appeared in NAHL's substantial-shareholder disclosure in the FY2025 Annual Report, initially flagged here as an unexplained new entrant. Further research reconciled it fully: NAHL's complete public "Holding(s) in Company" RNS record (17 filings, November 2024 to August 2026) contains exactly one reference to Sacisa or Patel — a 13 March 2025 filing disclosing Bhavesh Patel's personal beneficial interest in 5,737,517 shares (12.07% of the share count that day) as Sacisa Limited's own holding fell below 3%. Companies House confirms Patel has been Sacisa Limited's sole director since 2007, making Sacisa his own personal investment vehicle rather than an unrelated third party. The arithmetic resolves the apparent puzzle cleanly: 5,737,517 shares is exactly 11.90% of NAHL's FY2025 year-end share count of 48,226,103 — the same absolute holding, with the percentage drifting only because NAHL's own share count grew over the year. No further regulatory filing on this position appears anywhere in the 17-month record checked, consistent with it being unchanged throughout. No public activist conduct — requisitions, public letters, board-seat demands — was found for Patel, and he holds no other UK company directorship on record, which argues for "long-term, quiet, concentrated individual holder" over "activist investor." A separately-checked solicitor of the same name (Law Society ID 317863 / SRA 584489, in-house at the Medical Protection Society in Leeds) does not match on location, career timeline, or business relevance, and is very likely a different person. What remains genuinely unknown is why Patel holds this stake, and whether he has ever engaged privately with the Board — neither can be confirmed or ruled out from public records. See the companion workbook's Ownership tab for the full sourced timeline.

Beyond the ownership point, four further patterns recur consistently enough across six years of filings to be worth naming.

• A single structural headwind explains most of the period's revenue volatility. The 2021 whiplash reform and its continuing aftermath is cited as the primary driver of Personal Injury revenue trends in every one of the six annual reports reviewed — a reminder to read any single year's revenue change against this backdrop before attributing it to company-specific execution.
• A consistently well-timed structural response to that headwind. Converting the Personal Injury referral business into an SRA-regulated law firm (National Accident Law), completed substantially ahead of the 2021 reform taking effect, is a genuine strategic achievement that kept the business profitable through a period that could easily have produced sustained losses — even though it did not fully offset the market's long-run contraction, as the eventual FY2024 impairment showed.
• A clean audit record despite one very large non-cash write-down. No qualified audit opinions or going-concern material-uncertainty paragraphs were issued in any of the six years reviewed, including FY2024 despite a £39.1m net loss — the impairment was non-cash and the Group's cash generation and covenant position remained sound throughout, evidenced by net debt falling in every single year of the period without exception.
• A pattern of announced-but-unresolved strategic reviews. The FY2024-2025 Critical Care disposal process ran for well over a year before being abandoned with minimal public explanation, and was immediately followed by a further, still-open-ended "exploring alternative options to accelerate shareholder value" process (ongoing as of the July 2026 trading update). Prolonged strategic uncertainty of this kind is itself a recurring management-quality consideration for this name, distinct from the underlying operating performance, which has generally been competently delivered. No dividend has been paid since October 2019, consistent with a sustained debt-reduction priority (net debt down from £16.3m to £1.0m over the period) that shareholders have now waited six years to see reversed.

Value range

NAHL is valued here using EV/EBITDA as the primary multiple, cross-checked against EV/Revenue — the standard framework for a people-based, asset-light professional/legal-services marketing business, where every one of the five comparables used below is itself actually priced, in its own trading multiple or disclosed transaction, predominantly off EBITDA or earnings rather than revenue. This is the opposite emphasis from a technology/hardware company with a distorted earnings base, and deliberately so: NAHL is a services business, not a product business, and should be valued the way this specific industry actually prices itself. Both methods were checked against 5 sourced peer/transaction multiples (Frenkel Topping, Anexo, Gateley Holdings, Knights Group, and DWF Group) and built entirely from the primary filings above, deliberately without reference to NAH's current share price at any stage.

A notable research-quality finding here: three of these five comparables (Frenkel Topping, Anexo, and DWF) have been taken private in UK take-private transactions within roughly the last three years, leaving only Gateley and Knights as live, UK-listed trading comparables — a genuine scarcity of comparables that this document treats as a standing caveat rather than papering over by stretching the comparable set further from NAHL's actual business. The starting earnings base uses a 3-year average of underlying EBITDA (FY2023-FY2025) rather than the single latest year, because management's own July 2026 trading update explicitly guides that NAL settlement volumes — and the cash and profit they generate — will be notably lower in H2 2026, meaning FY2025's underlying EBITDA alone is flattered by settlement timing in a way FY2026 is guided not to repeat.

Full sensitivity model with editable assumptions, and the full 5-peer comparison with sourced multiples, is in the companion workbook's Valuation tab. Move any yellow input cell there and every downstream figure recalculates.

Why the two methods broadly overlap here, and how to read that

Unlike a business with a large one-off item distorting one of its two bases, the EV/EBITDA range (approximately 40-86p) and the EV/Revenue range (approximately 18-60p) here broadly overlap rather than sharply diverge — itself a finding worth naming. NAHL's revenue and underlying EBITDA both move together reasonably consistently once the 3-year averaging smooths the settlement-timing effect discussed above, which is a healthier valuation signal than a wide, irreconcilable divergence between the two methods would be (contrast this with KMK, an earlier company in this project series, where a single one-off licensing transaction caused its two valuation methods to diverge sharply).

A materially thinner market-check exists here than for a company with visible public sell-side consensus. NAHL's Nominated Adviser and sole broker, Allenby Capital, publishes regular research notes, but these are gated to institutional and professional-investor log-ins, and no public aggregator checked (MarketBeat, LSE.co.uk, Research Tree's public preview) surfaced a visible price target or consensus revenue/PBT figure for NAH. The central case here is therefore grounded against comparable-company multiples — a real, sourced market check — but not against any independent analyst view of NAHL specifically, which is stated plainly here rather than dressed up as more rigorous than it is. Separately, this valuation deliberately does NOT treat the three recent comparable take-privates, or NAHL's own ongoing "exploring alternative options" process, as inputs to the range — they are discussed as context in the companion workbook's Assumptions vs Market Expectations section, consistent with the standing rule of excluding price-sensitive market speculation from the fundamentals-based range.

Sum-of-the-parts (SOTP) cross-check: Consumer Legal Services and Critical Care valued separately

This cross-check was added in response to a third-party analysis (of unverified origin, supplied by the user) arguing NAHL's two divisions deserve materially different multiples — Critical Care (Bush & Co.) as a more defensive, specialty expert-witness/care-assessment business, versus CLS's continued exposure to the post-2021-whiplash-reform RTA claims market — and that this reveals a combined value of roughly £42m-£57m, well above this document's group-level range. That figure could not be reconciled: it implies a CLS EBITDA of only £1.7m-£2.9m, which is below the £4.4m underlying operating profit NAHL itself disclosed for that segment in its 27 January 2026 trading update (EBITDA cannot be below operating profit, since EBITDA equals operating profit plus depreciation and amortisation), and it did not appear to subtract the roughly £1.9m/year of unallocated central and PLC costs that sit outside both segments — a check that emerges directly from NAHL's own disclosed figures (CLS underlying operating profit of £4.4m plus Critical Care's £4.8m sums to £9.2m, £1.9m more than the £7.3m the Group actually reported).

Rebuilding the SOTP properly — using NAHL's own disclosed segment operating profit, allocating D&A between segments by revenue share, applying a deliberate multiple premium to Critical Care (5.0x-7.5x, capped at Frenkel Topping's actual 7.5x transaction multiple rather than extended further) over CLS (3.0x-5.5x, anchored to Knights and Anexo, the closest claims-marketing-model matches), and then subtracting the central costs capitalised at a constant 5.0x — produces a value-per-share range whose central case sits close to, but below, this document's own group-level EV/EBITDA high case, with only the high-case scenario (which requires both segments to simultaneously hit their most optimistic multiple) extending meaningfully past the group-level range. Full formulas, all editable, are in the companion workbook's Valuation tab.

This is the opposite conclusion from the external analysis that prompted it: differentiating the two segments and doing the arithmetic properly — correctly using NAHL's own disclosed operating profit and subtracting the central-cost drag — does not reveal a large pool of value the single-multiple group approach was missing. The largest source of uncertainty in this cross-check is the Critical Care multiple premium itself, which is a reasoned judgment overlay grounded in a single data point (Frenkel Topping's transaction multiple, itself only a partial business-model match for an expert-witness/specialty-healthcare-services business), not a verified peer set — a reader who does not accept that premium should weight the group-level primary range more heavily than this cross-check.

Limitations and what would sharpen this further

• None of the figures in this document or the companion workbook have been checked against a second, independent source beyond the primary filings read in this session. Per the project's standing rule, no number here should enter an investment decision until independently verified.
• NAHL discloses directors' and substantial shareholders' interests as percentages only, in every year reviewed — not underlying share counts. Where the companion workbook shows an "implied shares" figure, that is my own calculation (disclosed percentage multiplied by total shares in issue), clearly flagged as such, not a Company-disclosed figure.
• The Sacisa Limited / Bhavesh Patel stake (11.90%) has been investigated and its mechanics resolved — see the Recurring Themes discussion above and the companion workbook's Ownership tab. What remains genuinely unknown, and is not resolvable from public records, is Patel's motive for holding the stake and whether he has ever engaged privately with the Board.
• The sum-of-the-parts cross-check's segment D&A allocation (split by revenue share) and its Critical Care multiple premium are this document's own assumptions, not company-disclosed figures — flagged clearly in the companion workbook, and the least-certain inputs in this document.
• Two primary sources give James Saralis's confirmed CEO start date as one day apart (16 versus 17 August 2021) — flagged, not resolved, as an immaterial but genuine documentary inconsistency.
• The FY2020 Annual Report presented "Administrative expenses" as a single post-exceptional total on the statement face, while FY2021-FY2025 reports explicitly label the line "before exceptionals." To keep one consistent basis across all six years, the FY2020 figure used in the companion workbook's Income Statement tab was back-solved (Gross profit less Underlying operating profit) to match the later years' presentation convention — documented in a comment on that row; reported Operating profit for FY2020 is unaffected either way.
• This valuation range would sharpen materially with: the audited H1 2026 interim results (due late September 2026), which would show whether the guided H2 2026 NAL settlement slowdown materialised as expected; completion (or non-completion) of the announced Searches UK disposal; more detail on why the FY2024-2025 Critical Care sale process produced no acceptable offer; and, ideally, a second, independent sell-side view to triangulate against, given NAHL's broker coverage is effectively single-source and gated.
• This document deliberately does not compare the value range above to NAH's current market price. That comparison is the next, separate step in the process, to be taken only after the figures above have been checked.

NAHL Group plc · LSE AIM: NAH · Research prepared 29 August 2026

Built from six fiscal years of primary filings, read in chronological order without reference to the share price at any point. Every figure in the companion workbook traces to a row in the tables below. Where a figure is derived, assumed or taken from a secondary source, it is identified as such rather than presented alongside reported figures.

Document set

Statement-level provenance

Non-primary and flagged items

Standing limitations

Holdings cannot be tracked in share counts across the period, only in percentages, so dilution and register movements are visible only as proportions. Backing into counts would require assumptions the disclosures do not support, and none were made.

The FY2024 goodwill impairment of £39.9m is non-cash and is treated as such throughout. It does not flow into the cash-based measures.

Built from seven fiscal years of primary filings (FY2019-FY2025, year ended late August, a 52/53-week fiscal year — FY2024 was a 53-week year — plus the 29 January 2026 trading update and the 6 May 2026 H1FY2026 interim report), read in chronological order without reference to the share price at any point. FY2020 is derived from the FY2021 Annual Report's prior-year comparative column, as no standalone FY2020 annual report exists in the source set. Prepared 29 August 2026. Companion workbook: SNWS_multi_year_model.xlsx.

Executive summary

Smiths News plc is the UK's largest wholesale distributor of newspapers and magazines to retailers in England and Wales, operating under long-term, geographically exclusive publisher contracts within a structurally protected, effectively two-wholesaler market (the only other national player, Menzies Distribution, is now a subsidiary of the Polish logistics group InPost, having been fully acquired in October 2024). The single most important fact for reading this company's history is its own corporate diversification-and-refocusing arc: acquired by nobody, but itself diversifying beyond wholesale distribution from 2014 (renamed Connect Group plc, acquiring the loss-making Tuffnells Parcels Express business for over £100m), before unwinding that diversification — selling Tuffnells for just £15m in May 2020 and reverting to the Smiths News name in November 2020. The resulting historic goodwill impairments are the direct cause of seven consecutive years of negative net assets, reversed only in FY2025.

From FY2021 onward, once refocused as a single-segment, pure-play wholesale distributor, the business has been a case study in disciplined, cash-generative recovery: adjusted operating profit has held in a narrow £38-40m band every year since, net debt (on the Company's own primary "Bank Net Debt" measure) fell from an average of £98.8m in FY2020 to a NET CASH position by FY2025 and further into H1FY2026, and the dividend has grown from a 1.5p resumption in FY2021 to 8.55p (including a special dividend) by FY2025. FY2025 itself was a milestone year — the Company's first year of positive net assets in at least seven years, its first-ever net cash position, and continued recovery of the McColl's Retail Group receivable impaired in FY2022 following that customer's administration.

The industry structure is unusually favourable for cash generation, if not for growth: publishers award each geographic territory to one of two wholesalers via periodic tender, with contracts now extending to 2029-2037 following a wave of renewals in mid-2026, meaning competition is episodic rather than continuous. The principal risk is squarely on the demand side — a secular decline in print circulation — rather than on competitive share loss. Valuing the business using dividend yield as the primary method (the framework this specific type of mature, high-payout distribution business is actually priced on), cross-checked against free cash flow yield and EV/EBITDA, and built entirely without reference to SNWS's current share price, produces a primary range of approximately 62p (low) to 74p (central) to 93p (high) per share, with free-cash-flow-yield and EV/EBITDA cross-checks both converging on a somewhat higher central case of roughly 96-98p.

Company background

Smiths News plc demerged from WH Smith PLC in 2006 and has operated ever since as a wholesale distributor of newspapers and magazines, buying titles from publishers and delivering them to retailers — newsagents, supermarkets and convenience stores — across England and Wales under long-term, geographically exclusive contracts. Non-print "growth verticals" introduced from FY2023 onward — reverse-logistics recycling, books and home-entertainment distribution for national retailers, and final-mile delivery expansion — remain a small but rising share of revenue, growing 35% in H1FY2026 alone.

Between April 2014 and November 2020 the Company traded as Connect Group plc, a period of genuine diversification beyond its core distribution business: it acquired Tuffnells Parcels Express, a B2B bulk-freight and parcel carrier, for over £100m in November 2014, alongside a book-wholesaling business (Connect Books/Bertrams) and an Education & Care supplies division, both later disposed of. Tuffnells proved a costly misstep — its goodwill was substantially impaired across FY2018-FY2019 and the business was ultimately sold in May 2020 for just £15m. The Company formally reverted to the Smiths News name at Companies House in November 2020, a straightforward rebranding requiring no scheme of arrangement, takeover, or shareholder vote, marking the completion of its return to a pure-play newspaper/magazine wholesale focus. From FY2021 onward, Smiths News has been the Company's only IFRS 8 reportable segment.

The industry itself is a structural duopoly rather than an openly competitive market. The only other national wholesaler, Menzies Distribution, was sold by John Menzies plc to private equity firm Endless in 2018, before being fully acquired by the Polish parcel-locker and logistics group InPost in October 2024 and rebranded "InPost Newstrade" — it is no longer independent or UK-listed. Historical estimates put the wholesale-market split at roughly 55% Smiths News to 45% Menzies, and a wave of new publisher contract wins in mid-2026 (News UK, Associated Newspapers, and exclusive magazine deals with Frontline and Seymour running to 2037) has pushed contracted publisher revenue visibility to 93-96%. Because each geographic territory is awarded to a single wholesaler by periodic tender rather than contested through live pricing, competition in this industry is episodic — occurring only at multi-year contract renewal — rather than continuous; the Company's principal risk is the secular decline in print circulation, not competitive share loss.

A further structural feature worth understanding is the sale-or-return mechanic standard to newspaper and magazine wholesale: retailers return unsold copies, and the Company recognises revenue net of an estimate of expected returns. The Company also carried a legacy defined-benefit pension scheme (the WH Smith Pension Trust, News Section) inherited from its 2006 demerger, which was bought out and wound up between FY2021 and FY2022 with a net cash surplus returned to the Company — it has carried no ongoing defined-benefit pension liability since. A separate, unrelated legacy exposure persists from the Tuffnells divestment: Tuffnells itself (under its new owner) entered administration in June 2023, and the Pensions Regulator subsequently opened a formal investigation into that business's own legacy pension scheme, for which Smiths News remains the disclosed former sponsor, generating small recurring costs.

Development, year by year

FY2019 — the Connect Group diversification reaches its reckoning

As Connect Group PLC, the Company reported a statutory pre-tax loss of £37.6m, driven overwhelmingly by a £45.5m impairment of Tuffnells Parcels Express goodwill and other assets — the culmination of the 2014 diversification, which had paid over £100m for a business now being written down toward the £15m it would eventually be sold for the following year. Group revenue of £1,467.9m combined the core Smiths News wholesale-distribution segment (£1,303.3m) with Tuffnells (£164.6m). The core wholesale business itself remained solidly operating-profit-positive throughout (adjusted operating profit £29.5m), underscoring that this was a capital-allocation failure from an earlier strategic era, not an operational one.

Recognising and writing down a failed acquisition, however large, is the correct accounting response once the trading evidence no longer supports the carrying value, and this impairment appears to have been a genuine, overdue reckoning rather than a surprise. It does not, however, reflect well on the capital-allocation decision that led to the position in the first place, made under an earlier diversification strategy — a shrinking-to-nil intangible asset base over consecutive years is a pattern worth sitting with rather than dismissing.

FY2020 — Tuffnells finally exited, COVID disruption absorbed

The Company completed its exit from Tuffnells in May 2020, selling it for £15m — a stark crystallisation of the earlier acquisition's failure, but a decisive one. Statutory profit before tax returned to positive (£14.8m, aided by disposal accounting), and the continuing Smiths News business's own adjusted operating profit rose to £35.1m despite COVID-19 disruption to retail footfall. The Company also wrote off the remaining £5.7m of DMD (Dawson Media Direct, an inflight/travel-retail distribution business) goodwill as that channel collapsed during the pandemic. Statutory profit for the year overall remained negative (-£6.7m total) once Tuffnells' part-year trading loss and disposal loss are included.

Completing the Tuffnells divestiture — even at a nominal, value-destructive price relative to the original purchase — removed a persistent drag and allowed the Group to refocus entirely on its profitable core wholesale-distribution business; continuing to hold a loss-making, non-core asset indefinitely would have been the worse choice. Using the COVID disruption as cover to also clear out the DMD goodwill was reasonable, if opportunistic, balance-sheet housekeeping.

FY2021 — a clean refocusing year

The first full year as a single-segment, pure-play newspaper/magazine wholesaler following the November 2020 rename back to Smiths News plc. Statutory profit before tax of £30.6m and adjusted operating profit of £39.6m (a multi-year high at the time) reflected a cleaner, focused business. The legacy WH Smith Pension Trust defined-benefit scheme was bought out during the year, on the way to a full wind-up completed the following year with a net cash surplus. The ordinary dividend resumed at 1.5p, the first shareholder distribution since the Tuffnells-era turmoil.

This was a genuinely clean refocusing year — divesting the failed diversification, definitively de-risking the legacy pension liability, and resuming a shareholder distribution — executed without major missteps. The "Connect Group" era can reasonably be considered closed from this point.

FY2022 — absorbing a major customer shock without derailing the trajectory

Adjusted operating profit held broadly steady at £38.1m despite a significant customer shock: McColl's Retail Group, a major convenience-retail customer, entered administration in May 2022, triggering a £4.4m receivables impairment. The pension scheme wind-up was formally completed in February 2022 with the surplus received. The ordinary dividend was raised sharply to 4.15p.

Absorbing a large, unplanned customer-administration shock without it derailing full-year profitability or the dividend trajectory is a reasonable demonstration of the underlying business's resilience and of appropriately conservative provisioning against the McColl's exposure — an exposure the Company would go on to substantially recover over the following three years.

FY2023 — steady operations, a legacy liability resurfaces

A steady, unremarkable year on the operating numbers (adjusted operating profit £38.8m, broadly flat; dividend held at 4.15p), but a legacy liability resurfaced: Tuffnells itself — sold three years earlier and by then under an unrelated owner — entered administration in June 2023, prompting the Pensions Regulator to open a formal investigation into the legacy Tuffnells defined-benefit pension scheme, for which Smiths News remains the disclosed former sponsor. This generates a small but recurring cost and reputational overhang outside current management's control.

A competent, low-drama operating year, but the re-emergence of Tuffnells-related liability risk — now via the pensions route rather than the trading route — is a reminder that the costs of the 2014-2020 diversification era had not fully finished working their way through the Company's accounts, nearly a decade after the original acquisition.

FY2024 — a 53-week year, a refinancing, and the first special dividend

A 53-week fiscal year modestly inflated revenue and adjusted operating profit (by roughly £0.9m from the extra week), but also caused a one-off £15.7m working-capital cash outflow tied to publisher payment timing — a distortion the Company flagged explicitly rather than allowing it to be mistaken for operating weakness. More substantively, the Company refinanced its debt in May 2024 (a new £40m revolving credit facility plus a £10m accordion, with HSBC and Santander), enabling a formal capital-allocation policy that supported a materially higher total dividend of 7.15p, including the Company's first-ever special dividend (2.00p).

Proactively refinancing well ahead of any covenant pressure, and using the resulting flexibility to commit to a clearer, more generous capital-return policy, is good, forward-looking balance-sheet management — and transparently flagging the 53rd-week cash-flow distortion reflects well on disclosure quality.

FY2025 — a milestone year: net cash, positive net assets, and a larger special dividend

FY2025 was the strongest year of the seven reviewed on essentially every balance-sheet and capital-return metric. The Company achieved positive net assets (+£9.5m) for the first time in at least seven years, moved to a Bank Net Cash position (+£3.3m) for the first time in its history, raised the total dividend again to 8.55p (including a larger 3.00p special dividend), and saw the McColl's receivable effectively fully recovered — a further £3.7m impairment reversal, taking cumulative recovery to 98% of the original £5.5m. Adjusted operating profit held at £39.1m despite a 3% revenue decline, evidencing continued cost discipline and margin resilience against the secular print-volume headwind.

This represents the point at which the multi-year post-Tuffnells recovery plan can reasonably be judged to have succeeded. The consistent, multi-year McColl's recovery process — rather than writing the receivable off and moving on — also reflects credibly on the Company's collections and legal discipline.

H1FY2026 (interim, most recent data point — 6 May 2026 interim report and 29 January 2026 trading update; not scored)

Revenue fell 3.9% to £515.7m and adjusted operating profit fell 5.7% to £18.3m, pressured by the annualised National Insurance Contributions increase and continued technology investment, but Bank Net Cash grew further to £7.8m (from £3.3m at FY2025 year end) and free cash flow rose 59% to £21.2m. Growth-verticals revenue (recycling, books/home-entertainment, final-mile) grew 35%, with the Recycling division alone up 50%, and the Company secured its largest-ever single book-delivery contract in the period. Publisher revenue contracted through to 2029 rose to 96% following a Guardian Newspaper Group contract renewal, and management flagged expected H2FY2026 demand tailwinds from the FIFA Men's World Cup and an ongoing collectables sales cycle.

Two CFO transitions occurred within roughly a year: Paul Baker resigned in March 2025, George Cooper (the Group Financial Controller) served as an interim bridge CFO, and Richard Clay was appointed permanent CFO in February 2026, having been announced to the Board as early as July 2025. This is an area of financial-leadership discontinuity worth watching, though it was handled via an orderly, pre-announced internal-bridge succession rather than an unplanned vacancy.

Year-by-year summary

Full line-item detail, formulas, and citations are in the companion workbook. Figures in £m are rounded from the underlying Income Statement tab figures; PBT figures in parentheses denote losses. FY2020 is derived from the FY2021 Annual Report's comparative column (no standalone FY2020 annual report exists); FY2024 was a 53-week fiscal year.

Industry and structural quirks worth understanding

• A genuine, contractually-defined duopoly rather than an openly competitive market. Each geographic territory is awarded to one of two wholesalers (Smiths News or InPost-owned Menzies Distribution) via periodic publisher tender, with contracts now running years — some to 2037. Live price competition within a territory essentially does not exist; competition happens only episodically, at tender renewal.
• Sale-or-return revenue recognition. As is standard across newspaper/magazine wholesale, retailers return unsold copies and revenue is recognised net of an estimate of expected returns — a mechanic worth understanding before comparing SNWS's revenue recognition to a simpler product-distribution business.
• The Company's own 2014-2020 diversification-and-reversal arc (Connect Group era) is the single largest driver of comparability issues across this document's earlier years — the FY2019-FY2020 revenue step-down, the multi-year negative-equity position, and the FY2020 discontinued-operations charge are all consequences of the Tuffnells acquisition and its 2020 disposal, not of the core wholesale-distribution business, which has been operating-profit-positive in every single year reviewed.
• A legacy liability can outlive a clean disposal by years. Tuffnells was sold in May 2020, yet its own subsequent 2023 administration (under an unrelated new owner) triggered a Pensions Regulator investigation into its legacy pension scheme that still generates small costs for Smiths News as former sponsor in FY2025 and H1FY2026 — a reminder that divesting a failed business does not always fully sever exposure to it.
• Working-capital and payment-timing noise dominates single-year free-cash-flow comparisons. The 53rd-week distortion in FY2024, the McColl's receivable recoveries staged over FY2024-FY2025, and the FY2022 Tuffnells earn-out receipt all cause free cash flow to swing considerably year to year for reasons that are timing, not operating performance — multi-year averages and the Bank Net Debt/(Cash) trend are more informative than any single year's free cash flow figure.

Recurring themes across the period

Aberforth Partners LLP stake reduction, August 2026 — flagged, not yet confirmed in a Company filing. A TR-1 "Holding(s) in Company" RNS dated 4 August 2026, located via web search (Investegate/Kalkine Media) rather than a Smiths News annual report, shows Aberforth Partners LLP — the Company's largest shareholder throughout the period reviewed — reduced its stake from 17.21% to 15.913% of voting rights. This is a genuine regulatory disclosure, but it postdates the FY2025 Annual Report used as the primary source elsewhere in this document and has not yet been cross-checked against a Company filing; treat the reduced figure as indicative pending confirmation at the next interim or annual report. No public activist conduct or campaign was found associated with Aberforth or any other named substantial shareholder, and no classic UK small-cap activist name (Harwood Capital, Gatemore, Slater Investments, Metage, Hosking Partners) appears anywhere on the register searched.

Beyond the flagged shareholding movement, four further patterns recur consistently enough across seven years of filings to be worth naming.

• A single corporate-history fact explains most of the period's early comparability challenges. The 2014-2020 Connect Group diversification and its unwinding (the Tuffnells acquisition and disposal, and the associated goodwill impairments) is the primary driver of the FY2019-FY2020 revenue step-down and the multi-year negative-equity position — a reminder to read the earlier years of this document against that backdrop before attributing changes to the core wholesale business's own performance.
• A consistent, multi-year deleveraging and capital-return trajectory from FY2021 onward. Bank Net Debt fell from an average of £98.8m in FY2020 to a net cash position by FY2025, while the dividend grew from a 1.5p resumption to 8.55p (including special dividends) over the same period — a genuine, evidenced turnaround rather than a management assertion alone.
• Disciplined handling of one-off shocks and legacy liabilities. The McColl's administration (FY2022) was provisioned conservatively and then substantially recovered over the following three years; the Tuffnells legacy pension investigation (from FY2023) has been disclosed transparently as a small recurring cost rather than downplayed. Both point to reasonably conservative, transparent financial management.
• An orderly, if frequent, pattern of CFO succession planning. The CFO seat changed hands twice within roughly a year (Baker to interim Cooper to Clay), but via a pre-announced internal bridge rather than an unplanned vacancy — a materially more orderly succession pattern than an unexplained leadership gap would represent.

Value range

SNWS is valued here using dividend yield as the primary method, cross-checked against free cash flow yield and EV/EBITDA — the framework recommended by dedicated peer and market research as how this specific type of business is actually priced. The Company is run and communicated around an explicit capital-allocation and dividend policy (a 2x ordinary-dividend cover target, with special dividends once leverage targets are met) rather than around earnings growth, so its holders are best served pricing it on cash returned or generated relative to price, not on an earnings multiple. There is no listed pure-play UK newspaper/magazine wholesaler peer; the comparator set used to check the assumptions spans Bunzl (a quality/scale ceiling), DX Group and PayPoint (the closest operational and style matches), ME Group International (a "melting ice cube" re-rating template), and International Distribution Services/Royal Mail (a conceptually close but now-delisted comparator, taken private in June 2025).

The starting dividend base uses only the FY2025 ORDINARY dividend (5.55p), deliberately excluding the 3.00p special dividend component, since special dividends were only introduced from FY2024 and are explicitly a function of the balance sheet having reached a net-cash position — not yet a demonstrated, repeatable feature. The free cash flow and EBITDA bases both use 3-year averages (FY2023-FY2025) to smooth the FY2024 53rd-week working-capital distortion discussed above.

Full sensitivity model with editable assumptions, and the full peer comparison with sourced multiples, is in the companion workbook's Valuation tab. Move any yellow input cell there and every downstream figure recalculates.

Why the primary method is more conservative than the two cross-checks, and how to read that

The dividend-yield method's range (approximately 62-93p) sits below both the free-cash-flow-yield range (approximately 72-124p) and the EV/EBITDA range (approximately 76-125p), which converge closely on each other in their central cases (~96p and ~96p respectively). This is expected, not a contradiction: the dividend-yield method captures only DISTRIBUTED cash flow (the ordinary dividend), while SNWS retains a meaningful share of its free cash flow beyond that dividend for deleveraging and, more recently, special distributions — a required cash yield built only on the ordinary dividend will mechanically understate value relative to methods built on the fuller free-cash-flow or EBITDA base. The dividend-yield method is retained as the PRIMARY range specifically because it is the most conservative and the most directly grounded in a single, simple, audited, company-declared number, consistent with the standing preference for a defensible floor over an optimistic point estimate.

A further check worth naming explicitly: a required dividend/equity yield of 6.0%-9.0% implies only a 0.85-3.85 percentage-point premium over the 5.15% UK 10-year gilt yield (28 August 2026) — on the low side of the roughly 4-6 percentage-point total equity-risk-premium-and-size-premium territory that would typically be expected for a small-cap equity investment. This arguably argues for weighting the HIGH-CASE end of the yield assumption (i.e., the more conservative, LOWER-value 9.0% required yield) at least as heavily as the central case, rather than treating this range as biased toward the optimistic end. No SNWS-specific sell-side consensus multiple or price target was located via public sources in the research pass behind this document — the cross-checks above are grounded in comparable-company data only, not in any independent analyst view of SNWS itself.

Limitations and what would sharpen this further

• None of the figures in this document or the companion workbook have been checked against a second, independent source beyond the primary filings read in this session. Per the project's standing rule, no number here should enter an investment decision until independently verified.
• FY2020 is entirely a derived column, reconstructed from the FY2021 Annual Report's prior-year comparative — no standalone FY2020 annual report exists in the source set reviewed. Every FY2020 figure in this document and the companion workbook should be read with that provenance in mind.
• FY2024 was a 53-week fiscal year, which modestly inflated that year's revenue and adjusted operating profit but also caused a one-off £15.7m working-capital cash outflow — flagged wherever it materially affects a figure used in this document, but worth bearing in mind for any calculation not explicitly discussed here.
• The balance sheet is presented in condensed form in the companion workbook: the research pass extracted headline totals and the largest individual line items, with smaller unitemised components captured via an explicit, flagged balancing row rather than a full line-by-line reconstruction of the statutory balance sheet.
• The Aberforth Partners LLP stake reduction (17.21% to 15.913%, per an August 2026 TR-1 filing located via web search) has been investigated but not yet cross-checked against a Company filing — see the Recurring Themes discussion above and the companion workbook's Ownership tab.
• The equity-risk-premium and small-cap-size-premium data used to sense-check the required-yield assumptions are the weakest-sourced inputs in this document — a live, UK-specific figure was not confirmed in the research pass behind this valuation. A reader wanting to build a full DCF/DDM cross-check (which the now-contracted publisher revenue visibility to 2029-2037 would support unusually well) should pull current figures directly from Damodaran's dataset or Kroll's Cost of Capital Navigator.
• This document deliberately does not compare the value range above to SNWS's current market price. That comparison is the next, separate step in the process, to be taken only after the figures above have been checked.

Smiths News plc · LSE Main Market: SNWS · Research prepared 29 August 2026

Built from seven fiscal years of primary filings, read in chronological order without reference to the share price at any point. Every figure in the companion workbook traces to a row in the tables below. Where a figure is derived, assumed or taken from a secondary source, it is identified as such rather than presented alongside reported figures.

The fiscal year ends in late August and runs on a 52 or 53 week basis. FY2024 was a 53-week year, which modestly inflates revenue and profit and materially distorts one cash flow line. Both effects are flagged where they occur.

Document set

Statement-level provenance

Non-primary and flagged items

Standing limitations

Seven fiscal years are covered but only six were directly sourced. FY2020 exists in this model solely as the FY2021 report saw it.

The company changed its name and its shape during the period. FY2019 figures are Connect Group PLC's, covering a group that included a parcels business subsequently sold. Comparisons across the FY2019 to FY2021 boundary are comparisons across two different businesses, and the KPI tab records the corporate history for that reason.

One ownership item is post-period and secondary. It is shown separately rather than incorporated.

Built from five fiscal years of primary filings (FY2021-FY2025, year ended 30 June), plus the most recent interim report (H1FY2026, six months to 31 December 2025) and trading updates, read in chronological order without reference to the share price at any point. No FY2019 or FY2020 annual report exists in the source set reviewed — FY2021 is the earliest year covered. Prepared 29 August 2026. Companion workbook: TFW_multi_year_model.xlsx.

Executive summary

FW Thorpe plc is a UK-headquartered (Redditch) designer, manufacturer and distributor of professional lighting and lighting-control systems for commercial, industrial, healthcare, education and public-sector customers, trading through a group of subsidiary brands — principally Thorlux Lighting in the UK, alongside Lightronics and Famostar (Netherlands), Zemper Group (Spain and France, emergency lighting and evacuation signage) and SchahlLED (Germany). It is a genuine multi-generational family business: founded in 1936 by Frederick William Thorpe and his son Ernest Thorpe, floated on the London Stock Exchange in 1965, and still governed today with three serving directors from the founding family (grandsons Andrew and Ian Thorpe, and great-grandson James Thorpe) holding roughly 45% of the Company between them.

Unlike every other company reviewed in this project series, FW Thorpe has clean, undistorted statutory earnings — no impairments, no restructuring charges, and only a single exceptional item across five years (a FY2021 insurance-recovery CREDIT following a fire at its Lightronics facility). This is a genuine strength, and it is also why this valuation departs from the cash-flow or asset-based primary methods used for the other companies in this series: with earnings this clean, a straightforward P/E multiple is the most defensible primary lens, cross-checked against EV/EBITDA (material given the Company's substantial net-cash position) and dividend yield (given FW Thorpe's long progressive-dividend record).

The five years reviewed show a company being transformed by cash-funded, non-dilutive acquisition — Zemper (Spain, FY2022), a joint-venture investment in Ratio Electric B.V. (Netherlands, electric-vehicle charging products, FY2022) and SchahlLED (Germany, FY2023) — while maintaining a net-cash balance sheet throughout and never raising equity or taking on material debt to fund the expansion. FY2025 was a record year for profit before tax despite flat revenue, and the Company undertook its first-ever share buyback. Genuine, acknowledged trading softness has emerged in FY2025 and continued into H1FY2026 (German industrial recession affecting SchahlLED, a slower UK market), but management has issued no profit warning and continues to describe performance as broadly in line with expectations. Valuing the business on a P/E-primary, EV/EBITDA- and dividend-yield-cross-checked basis, built entirely without reference to TFW's current share price, produces a primary range of approximately 195p (low) to 260p (central) to 325p (high) per share.

Company background

FW Thorpe traces its history to 1936, when Frederick William Thorpe and his son Ernest Thorpe established the business making spun circular reflectors — the origin of what is now Thorlux Lighting. The Company expanded through the 1940s-1960s into linear fluorescent luminaires and the exterior and hazardous-area lighting markets, floated on the London Stock Exchange in 1965, moved to its current Redditch headquarters in 1989, made its first acquisition (Mackwell Electronics) in the early-to-mid 1990s, and transferred its listing to AIM in 2005, where it has traded ever since.

The Group internationalised steadily from the mid-2010s: a minority investment targeting the Spanish market and a lens-specialism acquisition in 2016, full ownership of Thorlux Australasia in 2017, and the acquisition of Famostar (Netherlands, emergency lighting) in 2018. FY2019 saw the Compact Lighting business merged into Thorlux and the Portsmouth facility sold, simplifying the UK manufacturing footprint just ahead of the COVID-19 pandemic, through which the Group kept all operations running from Group-owned property. The pace of international expansion then accelerated materially from FY2022 onward: Electrozemper (Spain, emergency lighting and evacuation signage) was acquired, a joint-venture investment was made in Ratio Electric B.V. (Netherlands, electric-vehicle charging products — now reported as the equity-accounted "Ratio Holding B.V." joint venture), and SchahlLED/Lumen (Germany) followed in FY2023 — all funded from the Group's own cash generation rather than debt or dilutive equity issuance.

Governance and ownership are inseparable from the Company's history. FW Thorpe remains a four-generation family business: founder Frederick William Thorpe's grandsons, Andrew Thorpe and Ian Thorpe, and great-grandson James Thorpe, all sit on the Board today, and between them the three serving family directors hold approximately 45% of the issued share capital — a controlling economic stake, though short of an outright voting majority. Day-to-day executive leadership has nonetheless been progressively professionalised and separated from the family: Mike Allcock (not a family member) combined the Chairman and Joint Group Chief Executive roles from 2017 until July 2024, when the roles were formally split — Allcock remaining as Chairman only, and Craig Muncaster (also not a family member, with the Group since 2010) becoming sole Group Chief Executive. James Thorpe's own executive role — Joint Managing Director of Thorlux Lighting — is a genuine day-to-day operating role with disclosed remuneration and normal long-term-incentive-plan participation, not a passive family sinecure. The full detail behind this — board independence classification, director shareholdings, substantial shareholders, and what the AIM-specific disclosure regime does and does not show about family control — is set out in the companion workbook's Ownership tab.

The lighting-manufacture industry itself is competitive and only moderately consolidated: Signify NV (formerly Philips Lighting) is the clear global scale leader, roughly thirty times FW Thorpe's revenue, spanning consumer, professional and horticultural lighting worldwide. The closest direct, pure-play, listed professional-lighting comparables are Zumtobel Group AG (Austria) and Fagerhult Group AB (Sweden) — both larger than FW Thorpe by revenue but competing in the same specification-led, professional/architectural lighting segment rather than the mass consumer or purely price-competitive tier. FW Thorpe's own management explicitly positions the business away from "foreign-made equipment, which is often more focused on price than service, quality and performance benefits," emphasising instead a "whole package" proposition of survey, design, supply and after-sales technical support — a defensible, if not uncontested, premium/specification niche, since Zumtobel and Fagerhult occupy broadly similar positioning at greater scale.

Development, year by year

FY2021 — recovering from a factory fire, the earliest year in the source set

Revenue of £117.9m and operating profit of £20.8m (after a net £1.6m insurance-recovery credit relating to a fire at the Lightronics, Netherlands facility) reflected a business still working through COVID-19 disruption and the aftermath of that fire. Despite this, the Company maintained its ordinary dividend (5.80p) and returned to profitable, cash-generative trading. No FY2019 or FY2020 annual report exists in the source set reviewed, so this is the earliest year that can be assessed directly from primary filings; FY2020 comparators referenced elsewhere are drawn only from this report's own prior-year column where explicitly cited.

Recovering a damaged facility to "improved results" (the Company's own later description) within the same or following year, while also holding the dividend through a genuinely disruptive year, is a reasonable early signal of operational resilience — though the true test of the multi-year trajectory only becomes visible from FY2022 onward, once cleaner year-on-year comparisons are possible.

FY2022 — the acquisition programme begins, funded entirely from cash

Revenue grew 22% to £143.7m and operating profit rose to £24.7m, the first year to reflect the Group's accelerated international expansion: the acquisition of Electrozemper (Spain) and a £4.96m joint-venture investment in Ratio Electric B.V. (Netherlands, electric-vehicle charging products) both completed during the year, contributing a small initial JV profit (+£228k) in their first partial period. A special dividend (2.27p, on top of a 5.85p ordinary dividend) was paid, reflecting continued confidence in the balance sheet even as cash was being deployed into acquisitions.

Funding two international transactions entirely from the Group's own cash generation, without raising debt or issuing dilutive equity, is a genuinely conservative and shareholder-friendly approach to acquisition-led growth — a pattern that recurs throughout the remaining years reviewed and is consistent with a family-controlled company managing its own balance sheet cautiously rather than reaching for leverage to accelerate growth.

FY2023 — SchahlLED completes the acquisition programme; margin growth lags revenue growth as the JV turns loss-making

Revenue grew a further 23% to £176.7m, and operating profit also grew, to £27.8m (+12.6%) — but that profit growth lagged well behind the revenue growth rate, a genuine margin-dilution year driven by the costs and integration of the SchahlLED (Germany) acquisition and, notably, the Ratio Holding B.V. joint venture turning loss-making for the first time (-£520k, having been marginally profitable in its first partial year). No special dividend was paid this year, and because the ordinary dividend rose only modestly (6.46p) while the FY2022 total (ordinary plus two special payments) had been considerably higher, the year-on-year total-dividend comparison reads as a steep decline if the ordinary and special components are not read separately — they are not comparable on a total-dividend basis without that context. From this year onward, the Company began separately reporting "Operating profit before acquisition-related adjustments," a non-GAAP measure excluding acquisition-intangible amortisation and contingent-consideration fair-value movements, reflecting the growing complexity of accounting for a now multi-acquisition group.

Completing a third acquisition within two years while margin growth lagged revenue growth is not, by itself, a red flag — integration costs in the year of completion are normal, and operating profit still grew in absolute terms — but the Ratio Holding joint venture turning loss-making in only its second year, and continuing to do so in every subsequent year reviewed, is a genuine, recurring soft spot worth tracking rather than dismissing as one-off integration noise.

FY2024 — a genuine governance improvement: Chairman and CEO roles separated

Revenue was roughly flat (£175.8m) but operating profit continued its steady climb to £30.6m (+10.1%), and profit before tax rose to £29.9m. The most consequential development of the year was governance rather than financial: in July 2024, the combined Chairman/Joint-Group-Chief-Executive arrangement held by Mike Allcock since 2017 was formally split, with Allcock remaining Chairman only and Craig Muncaster (Joint Group Chief Executive since 2017) becoming sole Group Chief Executive. A special dividend (2.50p) was reintroduced on top of a further-increased ordinary dividend (6.78p), and the Ratio Holding joint venture's loss widened again (-£826k), now a second consecutive year of deterioration.

Separating the Chairman and Chief Executive roles — bringing the Company into closer, though still not full, alignment with conventional UK governance expectations for role separation — is a genuine, voluntary improvement, not one forced by any external shareholder pressure (the family retains no independent-shareholder mechanism that would have compelled this). It reflects credibly on the Board's own governance judgement, even though the Board's overall independence balance remains thin by Main Market standards, as detailed in the companion workbook's Ownership tab.

FY2025 — a record profit year despite flat revenue, and the first-ever share buyback

Revenue was essentially flat (£175.2m, -0.3%) but operating profit rose to £32.1m (+4.7% on a statutory basis; the Company's own "before acquisition-related adjustments" measure rose a more modest +1.7%, £32.36m to £32.90m), a genuine margin-expansion year. FW Thorpe undertook its first-ever share buyback during the year (£3.14m), alongside a further-increased ordinary dividend (7.12p) though no special dividend this year. The Chairman's own commentary struck a more cautious tone than the headline profit figure alone would suggest — describing "the overall undertone... as one of conditions becoming harder," citing UK government-mandated operating-cost increases and signs of a UK market slowdown, with Germany (SchahlLED) explicitly in a segment-level recession (revenue there falling from roughly £15m to £11m) even as UK smaller subsidiaries and Zemper's newer product lines continued to grow well. The Ratio Holding joint-venture loss widened for a third consecutive year (-£1,360k).

Delivering a record profit year while the Chairman is simultaneously and transparently flagging harder trading conditions is a sign of credible, non-promotional disclosure — the Company is not hiding softening end-markets behind a strong headline number. Introducing a first-ever buyback in the same year as a genuine trading-conditions warning is a reasonable capital-allocation response for a net-cash business with no better use for the incremental cash at that point, though it is also, mechanically, a form of return that benefits the Thorpe family's own ~45% stake proportionately alongside all other shareholders. The Ratio Holding joint venture's now three-year losing streak is the one item in this year's results that most clearly warrants continued, close monitoring rather than being treated as settled.

H1FY2026 (interim, most recent data point — six months to 31 December 2025; not scored)

Revenue fell 2.4% to £81.7m and operating profit was roughly flat, with profit before tax up 3.1% and EPS up 2.7% — a "stable," on-plan performance in the Company's own words, though Lightronics and SchahlLED were both flagged as underperforming amid what the Company itself called "the widely acknowledged recession" in Germany's industrial sector. A subsequent AGM trading statement (20 November 2025) described results as "in line with last year's," with good starts at Zemper and Famostar and SchahlLED orders "improving every month" since late FY2025, while acknowledging "the general malaise seen elsewhere in UK and EU lighting markets" and that "the Group is finding it challenging to take a step forward in its revenues." No profit warning has been issued at any point through this period, and share buybacks have continued into mid-2026. FY2026 (year to 30 June 2026) final results were not yet due as of the primary sources reviewed for this document.

This reads as a genuinely softer, but managed and transparently communicated, trading environment rather than a deteriorating one — the absence of a profit warning across two consecutive reporting periods of acknowledged softness, combined with continued dividend growth and ongoing buybacks, is more consistent with a temporary macro/end-market headwind than with an operational problem specific to FW Thorpe.

Year-by-year summary

Full line-item detail, formulas, and citations are in the companion workbook. Sentiment and management-quality scores are subjective, analyst-assigned assessments (0-10 scale) reflecting the qualitative reading above, not derived from any formula. H1FY2026 is a memo-only data point in the narrative above and is not scored, since only a half-year is available.

Industry and structural quirks worth understanding

• AIM listing means a materially lighter shareholder-disclosure regime than the Main Market companies reviewed elsewhere in this project series. FW Thorpe follows AIM Rule 17 / Schedule Two paragraph (g): a once-a-year, annual-report-only disclosure of substantial shareholders (3%+ of voting rights), which explicitly EXCLUDES directors' own holdings — a materially lighter and less timely regime than the Main Market's continuous DTR5/TR-1 disclosure duty used at every other company in this series.
• A direct consequence of that AIM disclosure rule: the single most important ownership fact about this Company — that three serving Thorpe-family directors hold roughly 45% of the issued capital between them — does not appear anywhere in the "substantial shareholders" table. It is visible only by reading the Remuneration Report's director-shareholding disclosure, a step easy to skip if a reader relies on the substantial-shareholders table alone.
• Genuinely clean statutory earnings, unusual among the companies reviewed in this series. Across five years, the only exceptional item was a single insurance-recovery CREDIT (FY2021); there have been no impairments, no restructuring charges, and no distressed-accounting items of any kind. This is the reason a straightforward P/E multiple, rather than a cash-flow or asset-based method, is used as the PRIMARY valuation lens for this Company specifically.
• A non-GAAP "Operating profit before acquisition-related adjustments" measure exists only from FY2023 onward, once the Group had completed enough acquisitions (Zemper, SchahlLED) to generate material acquisition-intangible amortisation and contingent-consideration fair-value movements worth adjusting for. No comparable adjusted figure exists, or should be inferred, for FY2021 or FY2022.
• Ordinary and special dividends must be read separately, not as a combined "total dividend" series. Because special dividends were paid in FY2022 and FY2024 but not FY2023 or FY2025, a total-dividend series alone would read as a sharp, un-signalled cut in the years without a special payment, when in fact the ordinary dividend itself increased in every single year reviewed.
• The Ratio Holding B.V. joint venture (electric-vehicle charging products, Netherlands) is equity-accounted, not consolidated — its widening losses (FY2022: +£228k, FY2023: -£520k, FY2024: -£826k, FY2025: -£1,360k) appear as a single net "share of loss of joint venture" line rather than as itemised revenue/cost detail, limiting how precisely an outside reader can diagnose the cause of the deterioration from the primary filings reviewed.
• A legacy hybrid pension scheme is in SURPLUS throughout the period (£2.2m-£4.4m each year) but is NOT recognised as a balance-sheet asset, due to the IAS19 accounting standard's asset-ceiling restriction — the trustees retain discretion over the surplus, so the Company has no unconditional right to it. This is a balance-sheet-understatement quirk worth knowing before comparing FW Thorpe's reported net assets to a peer without an equivalent restricted surplus.

Recurring themes across the period

Family control is the central governance fact of this Company, and it is structurally under-disclosed by the applicable listing regime. Three serving Thorpe-family directors — Andrew Thorpe (grandson of founder Frederick William Thorpe), Ian Thorpe (also a grandson), and James Thorpe (great-grandson) — hold approximately 45% of issued capital between them, a controlling economic stake that AIM's Rule 17 disclosure regime keeps entirely outside the Company's own "substantial shareholders" table, since that table by rule excludes directors. Combined with a Board on which only one of six directors (Frans Haafkens) is independent, a minority shareholder has genuinely thinner structural protection here than at any Main Market company reviewed elsewhere in this project series. Nothing in the primary sources reviewed suggests this has been exploited to the detriment of minority holders — clean earnings, a conservative net-cash balance sheet, a long progressive-dividend record, and the voluntary 2024 Chairman/CEO role separation all point toward disciplined, minority-respecting stewardship rather than extraction — but the thinner structural check is a fact about the governance structure itself, independent of how well the family has behaved to date, and is worth continued monitoring at each future annual report rather than treated as a settled, resolved question. This mirrors the "trap versus value" framing this project has applied to other family-influenced situations: the evidence to date leans toward value, but the structural vulnerability that would make it a trap has not gone away.

Beyond the family-control theme, four further patterns recur consistently enough across the five years of filings reviewed to be worth naming.

• A genuinely clean, cash-funded international expansion. Three acquisitions/JV investments (Electrozemper, Ratio Electric B.V., SchahlLED) were completed within a two-year window (FY2022-FY2023), all funded from the Group's own cash generation without new debt or dilutive equity issuance — a disciplined, patient approach to acquisition-led growth consistent with a family-controlled company managing its own balance sheet cautiously.
• The Ratio Holding B.V. joint venture is the one recurring soft spot in an otherwise clean five-year record — a widening loss in every year since its FY2022 investment, now three consecutive years of deterioration by FY2025, and one that is genuinely difficult to diagnose in detail from the primary filings reviewed, since equity-accounted joint ventures disclose only a single net profit/loss line.
• Progressive, voluntary governance improvement even without external shareholder pressure. The July 2024 Chairman/CEO role separation was not forced by any activist or independent-shareholder campaign — the family's own ~45% stake would make such a campaign difficult to force through in any event — yet it happened anyway, a point in favour of the Board's own governance instincts.
• Genuine, transparently-communicated trading softness from FY2025 into H1FY2026, with no profit warning. Germany (SchahlLED) has been explicitly described by the Company as in industrial recession, and UK market conditions as harder, across two consecutive reporting periods — but the Company has continued to grow its ordinary dividend, initiate and continue share buybacks, and describe results as "in line with" or "stable" relative to expectations throughout, rather than issuing a warning. This reads as a genuine but currently well-managed macro headwind, not a company-specific operational problem.

Value range

FW Thorpe is valued here using a P/E multiple as the PRIMARY method, cross-checked against EV/EBITDA and a dividend-yield method — the framework recommended by dedicated peer and market research as suited to this specific business. Unlike every other company reviewed in this project series, FW Thorpe has clean, undistorted statutory earnings (no impairments, no exceptional charges beyond the single FY2021 insurance-recovery credit), which makes a straightforward earnings multiple the most defensible primary lens here rather than a fallback. EV/EBITDA is a necessary secondary check given the Company's substantial net-cash position, and dividend yield is a further cross-check given FW Thorpe's long, progressive-dividend, "dividend hero" profile. The comparator set used to check the assumptions comprises three direct, listed professional-lighting peers (Zumtobel Group AG, Fagerhult Group AB, Signify NV), a UK small-cap industrial quality-discount floor (Renold plc), and three larger, higher-multiple UK industrial compounders excluded from the primary anchoring as scale-driven outliers (Halma, Rotork, Volution).

The starting point uses only the single latest year (FY2025 basic EPS of 21.69p), rather than a multi-year average, since FW Thorpe's earnings are clean and have grown in every year reviewed — averaging in weaker, superseded years would understate rather than sharpen the estimate. The EV/EBITDA method uses FY2025 EBITDA on the Company's own disclosed segmental basis (£41.612m); the dividend-yield method uses the FY2025 ORDINARY dividend only (7.12p), deliberately excluding the special dividend, since special dividends have not been paid in every year and are not yet a reliably repeatable feature.

Full sensitivity model with editable assumptions, and the full peer comparison with sourced multiples, is in the companion workbook's Valuation tab. Move any yellow input cell there and every downstream figure recalculates.

Why the three methods diverge, and how to read that

The dividend-yield method's range (approximately 158-237p) sits meaningfully below both the P/E range (approximately 195-325p) and the EV/EBITDA range (approximately 215-376p). This is expected, not a contradiction: the dividend-yield method captures only the ordinary dividend FW Thorpe chooses to distribute, while the Company retains the substantial majority of its earnings for acquisitions, buybacks and organic reinvestment rather than paying it all out — a required-yield method built only on the distributed dividend will mechanically understate the value of a growth-reinvesting compounder like this one. It is retained here as a tertiary cross-check, not the primary method, for exactly that reason. The P/E and EV/EBITDA ranges, by contrast, both capture the full earnings or cash-generation base rather than only the distributed portion, and their central cases (260p and 286p respectively) sit reasonably close together, which is a reassuring degree of cross-method convergence for the primary range.

A further check worth naming explicitly: no TFW-specific sell-side consensus P/E target was located via public sources in the research pass behind this document — as an AIM small-cap, formal analyst coverage is likely thin, and the assumptions above are grounded in comparable-company data only, not in any independent analyst view of FW Thorpe itself. The required dividend yield range (3.0%-4.5%) implies only a modest premium over the 5.15% UK 10-year gilt yield (28 August 2026) at the low end of the range, and in fact sits BELOW the gilt yield at the high end — an unusual-looking result that is itself a further reason the dividend-yield method is treated as the most conservative cross-check rather than a method to be read in isolation; it reflects the market pricing a low-payout, high-retention compounder primarily on growth and capital appreciation rather than on income.

Limitations and what would sharpen this further

• None of the figures in this document or the companion workbook have been checked against a second, independent source beyond the primary filings read in this session. Per the project's standing rule, no number here should enter an investment decision until independently verified.
• No FY2019 or FY2020 annual report exists in the source set reviewed — FY2021 is the earliest year that can be assessed directly from a primary filing for this Company, which is a shorter run than the other companies reviewed in this project series.
• The balance sheet is presented in condensed form in the companion workbook: the research pass extracted headline totals and the largest individual line items, with smaller unitemised components captured via an explicit, flagged balancing row rather than a full line-by-line reconstruction of the statutory balance sheet.
• The Ratio Holding B.V. joint venture's widening losses are disclosed only as a single net line in the primary filings reviewed — the underlying revenue, cost, or write-down drivers behind the deterioration could not be diagnosed in more detail from the sources available in this pass.
• A 24 December 2025 Investegate RNS showing the Brangwin Trust's substantial shareholding reduced to approximately 3.96% has been noted but not yet cross-checked against a Company annual report — see the companion workbook's Ownership tab. Because of AIM's annual-only Rule 17 disclosure regime, the next confirmation point for this figure is the FY2026 Annual Report, not a continuous filing.
• The equity-risk-premium and small-cap-size-premium data used to sense-check the required-yield assumptions are the weakest-sourced inputs in this document — a live, UK-specific figure was not confirmed in the research pass behind this valuation, and no full discounted-cash-flow model has been built. A reader wanting that additional cross-check should pull current figures directly from Damodaran's dataset or Kroll's Cost of Capital Navigator first.
• This document deliberately does not compare the value range above to FW Thorpe's current market price. That comparison is the next, separate step in the process, to be taken only after the figures above have been checked.